Skip to main contentSkip to navigation
BCLP logo
  • People People

  • SectorsAerospace & DefenseEnergy TransitionFinancial InstitutionsFood & AgribusinessHealthcare & Life SciencesReal EstateRetail & Consumer Products Sports, Media & Entertainment

    View all sectors View all sectors

    Practice areasFinanceInvestigationsLitigationReal EstateRegulation, Compliance & AdvisoryTax & Private ClientTransactions

    View all practice areas View all practice areas

  • News News

    AwardsDiversityPro Bono

    View all News View all News

    Insights Insights

    BlogsPodcastsWebinars

    View all Insights View all Insights

  • Perspectives Perspectives

    Emerging Themes 2026Getting Deals DoneThe Sustainability Imperative Confronting CorruptionClass Actions
    Trending TopicsArtificial IntelligenceThe Corporate Transparency ActTrump Second Term: Legal Tracker
  • Events Events

    Webinars
  • About us About us

    Pro bono & CommunityInclusion & DiversityResponsible Business

    Client stories Client stories

    Media inquiries Media inquiries

  • Careers
  • Locations
  • Subscribe
BCLP logo
People
Capabilities
News & Insights
BCLP logo

Paul A. Barrs


Paul A. Barrs
  1. People

Paul A. Barrs

Paul A. Barrs

Counsel


St. Louis

Paul A. Barrs
  1. People

Paul A. Barrs

Paul A. Barrs

Counsel


St. Louis

Paul A. Barrs

Counsel

St. Louis

T: +1 314 259 2376

VcardVcard
Download PDFDownload PDF
Print
Share
  • Biography

Biography

Paul Barrs has a deep and diverse antitrust practice, with significant experience in counseling and compliance, transactional analysis, defense of merger and conduct investigations, and regulatory filings with the Federal Trade Commission and U.S. Department of Justice Antitrust Division.

Paul counsels clients on antitrust issues arising from their day-to-day competitive concerns, and from proposed mergers and acquisitions involving competitors.  He has deep experience in managing  information exchange issues, both for trade associations and other clients, and in the premerger context.  He has negotiated and devised language for dozens of M&A agreements, customized to allocate and manage antitrust risk associated with potential divestitures and other remedies. 

Paul is a leader in our firm’s joint defense efforts defending merger investigations on a multijurisdictional basis, helping to devise strategies around market definition and competitive dynamics. 

 

Admissions

  • Missouri, 2017
  • California, 2003

Education

  • University of California-Hastings, J.D., 2003
  • University of California-Los Angeles, B.A., with honors, 1999

Related Capabilities

Antitrust & Competition Antitrust & Competition

Investigations Investigations

Litigation & Dispute Resolution Litigation & Dispute Resolution

Regulation, Compliance & Advisory Regulation, Compliance & Advisory

  • Antitrust & Competition

  • Investigations

  • Litigation & Dispute Resolution

  • Regulation, Compliance & Advisory

Related Insights

View All Related InsightsIcon: arrow

News
Mar 02, 2026

BCLP Advises Envision Radiology on Acquisition of Rezolut Holdings and associated Credit Financing

Insights
Feb 23, 2026

HSR in Flux: New Filing Requirements Collide with Federal Court Ruling

On February 12, 2026, a federal district court in the Eastern District of Texas vacated the Federal Trade Commission’s new Hart‑Scott‑Rodino Act premerger notification form, concluding that in its 2025 comprehensive overhaul of the nearly 50-year old form, the agency exceeded its statutory authority and acted arbitrarily and capriciously under the Administrative Procedure Act. Although the court ordered the new form set aside, the Fifth Circuit has issued an administrative stay while it considers the FTC’s emergency motion for a stay pending appeal. As a result, the new HSR form remains in effect at this time. Parties preparing HSR filings should be aware that filing requirements may shift quickly depending on the Fifth Circuit’s forthcoming decision.
Insights
Feb 13, 2026

California Adopts New Antitrust Filing Requirements, Adding Obligations for HSR Act Filers in 2027

Insights
Jan 30, 2026

Seal the Valve, But Not the Deal: Court Blocks Edwards Lifesciences’ Pre Commercial Merger

A recent federal district court decision in FTC v. Edwards Lifesciences adds another win to U.S. enforcers’ efforts to apply traditional antitrust principles to mergers involving early‑stage or pre‑commercial products. In granting the FTC a preliminary injunction blocking Edwards’ acquisition of JenaValve, the court endorsed an expansive “pre‑commercial innovation market” theory—accepting that the two companies were actively competing not in a traditional commercial market, but in the research, development, and anticipated commercialization of next‑generation transcatheter aortic valve replacement (TAVR‑AR) devices.[1] Although no TAVR‑AR device is yet FDA‑approved for commercial sale in the United States, the court found that the companies’ efforts to progress through FDA trials constituted meaningful competitive interaction.[2] Relying on the 2023 Merger Guidelines, the ruling underscores the growing institutional acceptance of research and development-based theories of harm.  For clients, Edwards Lifesciences represents a helpful reminder of the import of antitrust counsel advising on potential transactions and reviewing deal terms as early as possible in the process, even when there is no present commercial competition between an acquirer and a target, so long as there is specific evidence of competition in innovation or R&D.  
Insights
Jan 15, 2026

All A-Board? Not so Fast: Private Equity and Family Offices Should Take Note of New Thresholds for Clayton Act Prohibition on Interlocking Directorates

Insights
Jan 15, 2026

FTC Announces 2026 HSR Act Thresholds and Filing Fee Schedule

News
Jun 11, 2025

BCLP Recognized in Mergers & Acquisitions’ Top 2025 Middle-Market Deals of the Year for Role in New Era–’47 Transaction

News
Apr 24, 2025

BCLP Advises AMMO, Inc. on Sale of Manufacturing Assets to Leading Ammunition Maker Olin Winchester

News
Apr 03, 2025

BCLP advises Terrestrial Energy Inc. in Milestone move to become first publicly traded molten salt nuclear reactor developer

Related Insights

News
Mar 02, 2026
BCLP Advises Envision Radiology on Acquisition of Rezolut Holdings and associated Credit Financing
Insights
Feb 23, 2026
HSR in Flux: New Filing Requirements Collide with Federal Court Ruling
On February 12, 2026, a federal district court in the Eastern District of Texas vacated the Federal Trade Commission’s new Hart‑Scott‑Rodino Act premerger notification form, concluding that in its 2025 comprehensive overhaul of the nearly 50-year old form, the agency exceeded its statutory authority and acted arbitrarily and capriciously under the Administrative Procedure Act. Although the court ordered the new form set aside, the Fifth Circuit has issued an administrative stay while it considers the FTC’s emergency motion for a stay pending appeal. As a result, the new HSR form remains in effect at this time. Parties preparing HSR filings should be aware that filing requirements may shift quickly depending on the Fifth Circuit’s forthcoming decision.
Insights
Feb 13, 2026
California Adopts New Antitrust Filing Requirements, Adding Obligations for HSR Act Filers in 2027
Insights
Jan 30, 2026
Seal the Valve, But Not the Deal: Court Blocks Edwards Lifesciences’ Pre Commercial Merger
A recent federal district court decision in FTC v. Edwards Lifesciences adds another win to U.S. enforcers’ efforts to apply traditional antitrust principles to mergers involving early‑stage or pre‑commercial products. In granting the FTC a preliminary injunction blocking Edwards’ acquisition of JenaValve, the court endorsed an expansive “pre‑commercial innovation market” theory—accepting that the two companies were actively competing not in a traditional commercial market, but in the research, development, and anticipated commercialization of next‑generation transcatheter aortic valve replacement (TAVR‑AR) devices.[1] Although no TAVR‑AR device is yet FDA‑approved for commercial sale in the United States, the court found that the companies’ efforts to progress through FDA trials constituted meaningful competitive interaction.[2] Relying on the 2023 Merger Guidelines, the ruling underscores the growing institutional acceptance of research and development-based theories of harm.  For clients, Edwards Lifesciences represents a helpful reminder of the import of antitrust counsel advising on potential transactions and reviewing deal terms as early as possible in the process, even when there is no present commercial competition between an acquirer and a target, so long as there is specific evidence of competition in innovation or R&D.  
Insights
Jan 15, 2026
All A-Board? Not so Fast: Private Equity and Family Offices Should Take Note of New Thresholds for Clayton Act Prohibition on Interlocking Directorates
Insights
Jan 15, 2026
FTC Announces 2026 HSR Act Thresholds and Filing Fee Schedule
News
Jun 11, 2025
BCLP Recognized in Mergers & Acquisitions’ Top 2025 Middle-Market Deals of the Year for Role in New Era–’47 Transaction
News
Apr 24, 2025
BCLP Advises AMMO, Inc. on Sale of Manufacturing Assets to Leading Ammunition Maker Olin Winchester
News
Apr 03, 2025
BCLP advises Terrestrial Energy Inc. in Milestone move to become first publicly traded molten salt nuclear reactor developer
Icon: arrow

Back to top

BCLP logo
  • People
  • Capabilities
  • Practice Areas
  • Sectors
  • News & Insights
  • Awards
  • Blogs
  • News & Events
  • Insights
  • Webinars
  • Perspectives
  • Getting Deals Done
  • Emerging Themes
  • The Sustainability Imperative
  • About us
  • Careers
  • Locations
  • Subscribe
  • Legal notices
  • Privacy notice
  • Modern Slavery Act
  • Cookie policy
  • UK Transparency Rules
  • Tax Information
  • Media inquiries
Icon: linkedin

© 2026 Bryan Cave Leighton Paisner LLP